BG104824A - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists

Info

Publication number
BG104824A
BG104824A BG104824A BG10482400A BG104824A BG 104824 A BG104824 A BG 104824A BG 104824 A BG104824 A BG 104824A BG 10482400 A BG10482400 A BG 10482400A BG 104824 A BG104824 A BG 104824A
Authority
BG
Bulgaria
Prior art keywords
vitronectin receptor
receptor antagonists
restenosis
osteoporosis
atherosclerosis
Prior art date
Application number
BG104824A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wolliam MILLER
John Gleason
Dirk Heerding
James Samanen
Irene Uzinskas
Peter Manley
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG104824A publication Critical patent/BG104824A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG104824A 1998-03-10 2000-10-03 Vitronectin receptor antagonists BG104824A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11
PCT/US1999/005232 WO1999045927A1 (en) 1998-03-10 1999-03-10 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
BG104824A true BG104824A (en) 2001-05-31

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104824A BG104824A (en) 1998-03-10 2000-10-03 Vitronectin receptor antagonists

Country Status (24)

Country Link
EP (1) EP1061921A4 (xx)
JP (1) JP2002506033A (xx)
KR (1) KR20010041812A (xx)
CN (1) CN1299282A (xx)
AP (1) AP2000001898A0 (xx)
AR (1) AR015241A1 (xx)
AU (1) AU758498B2 (xx)
BG (1) BG104824A (xx)
BR (1) BR9908636A (xx)
CA (1) CA2323208A1 (xx)
CO (1) CO5080762A1 (xx)
DZ (1) DZ2741A1 (xx)
EA (1) EA200000921A1 (xx)
HU (1) HUP0101143A3 (xx)
ID (1) ID26223A (xx)
IL (1) IL138245A0 (xx)
NO (1) NO20004503L (xx)
OA (1) OA12189A (xx)
PE (1) PE20000323A1 (xx)
PL (1) PL342881A1 (xx)
SK (1) SK13292000A3 (xx)
TR (1) TR200002625T2 (xx)
UY (2) UY25421A1 (xx)
WO (1) WO1999045927A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
DE19939980A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
PE20020665A1 (es) 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
EP1721905A4 (en) * 2004-03-05 2009-11-18 Taisho Pharmaceutical Co Ltd THIAZOLE DERIVATIVE
UA87854C2 (xx) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена
MX2007013198A (es) 2005-04-20 2008-03-24 Johnson & Johnson Moduladores de trombina de n-oxido de piridina fluorado y procedimiento para n-oxidacion de heteroarilos que contienen nitrogeno.
AU2014312756B2 (en) * 2013-08-29 2018-11-22 Kyoto Pharmaceutical Industries, Ltd. Novel aromatic compound and use thereof
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL327626A1 (en) * 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
IL125034A0 (en) * 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists

Also Published As

Publication number Publication date
TR200002625T2 (tr) 2000-12-21
UY25519A1 (es) 1999-12-13
EP1061921A1 (en) 2000-12-27
EA200000921A1 (ru) 2001-04-23
HUP0101143A3 (en) 2002-12-28
IL138245A0 (en) 2001-10-31
CO5080762A1 (es) 2001-09-25
NO20004503L (no) 2000-10-10
ID26223A (id) 2000-12-07
AP2000001898A0 (en) 2000-09-30
CA2323208A1 (en) 1999-09-16
WO1999045927A1 (en) 1999-09-16
EP1061921A4 (en) 2005-03-30
OA12189A (en) 2006-05-09
HUP0101143A2 (hu) 2001-08-28
AU758498B2 (en) 2003-03-20
AU2903399A (en) 1999-09-27
UY25421A1 (es) 2001-07-31
CN1299282A (zh) 2001-06-13
SK13292000A3 (sk) 2001-06-11
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
AR015241A1 (es) 2001-04-18
BR9908636A (pt) 2002-01-08
PL342881A1 (en) 2001-07-16
PE20000323A1 (es) 2000-05-24
NO20004503D0 (no) 2000-09-08
KR20010041812A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
BG104824A (en) Vitronectin receptor antagonists
MX9805253A (es) Antagonistas del receptor de vitronectina.
AP1463A (en) Vitronectin receptor antagonists.
EP0961613A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HUP0002971A3 (en) Plant extracts for the treatment of increase bone resorption
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
NZ329431A (en) Purine derivatives and medicaments thereof
EP0793489A4 (en) AGENTS FOR TREATING SKIN DISEASES
NO951498D0 (no) Farmasöytisk preparat for behandling av osteoporose
MY124786A (en) Bis-arylsulfones
PL337361A1 (en) Chalkones of antiproliferative activity
DE60015508D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
BG105651A (en) Vitronectin receptor antagonist
MXPA02001204A (es) Compuestos calciliticos.
DE69911017D1 (en) Arylsulfonanilid-phosphate
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
WO2000007544A3 (en) Vitronectin receptor antagonists
GB9920910D0 (en) Novel chalcones
HUP0103657A3 (en) Pharmaceutically active plant preparation for the treatment of migraine
NZ506750A (en) Vitronectin receptor antagonists useful in the treatment of inflammation, cancer and cardiovascular disorders
AU5246598A (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
MXPA02002486A (es) Uso de dexrazoxano para tratar la psoriasis.
ITBO990597A0 (it) Ortesi ortopedica per il trattamento di epicondiliti .